Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will deliver a presentation on February 12th, 2025, at 8:40 am ET.
Interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (Nasdaq: CMPS), un'azienda biotecnologica focalizzata sull'innovazione nella salute mentale, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Salute Oppenheimer. La direzione dell'azienda presenterà un intervento il 12 febbraio 2025, alle 8:40 ora ET.
Le parti interessate possono accedere a una trasmissione audio dal vivo della presentazione attraverso la pagina 'Eventi' nella sezione Investitori del sito web di Compass. La registrazione della trasmissione rimarrà disponibile per 30 giorni dopo l'evento.
Compass Pathways (Nasdaq: CMPS), una compañía biotecnológica enfocada en la innovación en salud mental, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La gestión de la compañía realizará una presentación el 12 de febrero de 2025, a las 8:40 am ET.
Las partes interesadas pueden acceder a una transmisión de audio en vivo de la presentación a través de la página de 'Eventos' en la sección de Inversores del sitio web de Compass. La grabación de la transmisión estará disponible durante 30 días después del evento.
컴파스 패스웨이즈 (Nasdaq: CMPS)는 정신 건강 혁신에 중점을 둔 생명공학 회사로, 오펜하이머 제35회 연례 헬스케어 생명 과학 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 2025년 2월 12일, 오전 8시 40분 ET에 발표를 진행할 예정입니다.
관심 있는 분들은 컴파스 웹사이트의 투자자 섹션에 있는 '이벤트' 페이지를 통해 발표의 라이브 오디오 웹캐스트에 접근할 수 있습니다. 웹캐스트 녹음은 이벤트 후 30일 동안 제공될 예정입니다.
Compass Pathways (Nasdaq: CMPS), une entreprise de biotechnologie axée sur l'innovation en santé mentale, a annoncé sa participation à la 35ème Conférence Annuelle sur les Sciences de la Santé d'Oppenheimer. La direction de la société présentera une intervention le 12 février 2025, à 8h40 ET.
Les parties intéressées peuvent accéder à un webinaire audio en direct de la présentation via la page 'Événements' dans la section Investisseurs du site Web de Compass. L'enregistrement du webinaire restera disponible pendant 30 jours après l'événement.
Compass Pathways (Nasdaq: CMPS), ein biotechnologisches Unternehmen, das sich auf Innovationen im Bereich der psychischen Gesundheit konzentriert, hat seine Teilnahme an der 35. jährlichen Oppenheimer Konferenz für Gesundheitswissenschaften angekündigt. Das Management des Unternehmens wird am 12. Februar 2025, um 8:40 Uhr ET eine Präsentation halten.
Interessierte Parteien können über die Seite 'Veranstaltungen' im Investorenbereich der Compass-Website auf einen Live-Audio-Webcast der Präsentation zugreifen. Die Aufnahme des Webcasts wird 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthesized psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the
We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We have completed an open label phase 2 study of COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD), and we are currently conducting a phase 2 clinical study in anorexia nervosa.
Compass is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205104883/en/
Enquiries
Media: Media, media@compasspathways.com
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
Source: Compass Pathways plc
FAQ
When is Compass Pathways (CMPS) presenting at the Oppenheimer Healthcare Conference 2025?
How long will the CMPS Oppenheimer Conference presentation webcast be available?
Where can I watch Compass Pathways' (CMPS) Oppenheimer Conference presentation?
Which conference is Compass Pathways (CMPS) participating in February 2025?
